Betting against stocks is widely considered to be a norm in the investment industry. Most investors have been reported to gain significant funds from making the right investment choices on specified stocks. However, none could have fathomed when SahmAdrangi pulled an unprecedented move by raising a whopping $100 million and betting against a single stock. Commonly known as short selling, Kerrisdale Capital Management’s chief investment officer undeniably grabbed the headlines as he pursues unchartered waters in the investment industry.
Often, investment managers opt to raise capital and focus on particular investment options such as residential mortgage securities and distressed energy companies. However, the chief investment officer made the bold decision to pursue an alternative route to short the stock of a highly anticipated public enterprise. According to Adrangi, the company made significant progress by raising such funds within a short duration. More importantly, Kerrisdale Capital Management made the unanimous decision to take a $10 billion company and strive to ensure everyone comprehends its insights. To reiterate such comments, Shane Wilson, a brilliant analyst at the firm shed some insight into the upcoming campaign with the sole intention of developing websites, reports, and videos to convince investors with their presentation.
Slated for public unveiling in mid-May, the company spokesperson reiterated that the vast funds had been in play in the acquisition of stocks to cement its position in the new company. Kerrisdale Capital Management’s reputation as a leading investment enterprise remains unrivaled. Since its formation, the company has successfully managed over $500 million worth of company assets including taking the company public as well as building a stellar reputation based on their exceptional betting history.
The capable CEO has played an active role in the company’s development and more so, turning a $1 million investment into a $150 million company valuation. Before publishing research and short selling, Adrangi offered his perspective on underperforming longs, overhyped shorts, and stocks which are surprisingly misunderstood by most analysts. Alternatively, the CEO gained prominence by working his way up through various companies such as Lihua International, China-Biotics, China Marine Food Group and others. While at Kerrisdale, Adrangi focused on harnessing the company’s biotechnology sector and partnering with companies such as Zafgen, Sage Therapeutics, and Bavarian Nordic.